Actively Recruiting
Phase 3 Study of Becotatug Vedotin Plus Sintilimab with Chemoradiotherapy Versus Gemcitabine and Cisplatin Induction Chemotherapy in High-Risk Locally Advanced Nasopharyngeal Carcinoma
Led by First Affiliated Hospital of Guangxi Medical University · Updated on 2026-03-16
266
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of a new treatment approach for patients with high-risk locally advanced nasopharyngeal carcinoma LANPC. This phase III clinical trial compares an experimental regimen including Becotatug Vedotin induction therapy followed by concurrent chemoradiotherapy CCRT combined with neoadjuvant and adjuvant sintilimab, against the standard treatment of gemcitabine plus cisplatin GP induction chemotherapy followed by CCRT. The study aims to provide evidence on improving 3-year event-free survival and other important outcomes like overall survival and quality of life in this patient group. Participants are randomly assigned to one of two groups. The experimental group receives three cycles of Becotatug Vedotin and sintilimab every three weeks, followed by CCRT with cisplatin and nine cycles of adjuvant sintilimab. The control group receives three cycles of gemcitabine plus cisplatin chemotherapy every three weeks before CCRT. All patients undergo intensity-modulated radiotherapy IMRT with a precise radiation dose over 33 fractions. The study includes detailed protocols for adjusting drug doses and monitoring side effects according to standard criteria. Throughout the study, participants will be closely monitored for treatment response, adverse events, and quality of life using validated scales and laboratory tests. Researchers will assess survival outcomes and track safety for up to three years. Biomarker analysis will also be performed to explore personalized treatment options. Patients health status, blood counts, organ function, and potential side effects will be regularly evaluated to manage treatment safely during the trial period.
CONDITIONS
Brief Title
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Research Team
M
Min Kang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here